Background and purpose: Angiotensin receptor-NEP inhibitor (ARNi), which includes an angiotensin receptor blocker (ARB) and a neprilysin inhibitor (NEPi), has been proven safe and effective for treating heart failure with reduced ejection fraction (HF-REF). S086 is a novel single-molecule ARNi that includes the molecular moieties of EXP3174 (the active metabolite of the ARB losartan) and sacubitril (a NEP inhibitor prodrug) in a 1:1 M ratio. We performed preclinical animal model studies to evaluate the efficacy of S086 in treating HF.
Experimental approach: Rat and dog models of myocardial ischemia-induced chronic heart failure were used in this research.
Principal results: The oral administration of S086 dose-dependently lowered the heart weight index, attenuated cardiac fibrosis, and improved left ventricular ejection fraction, shortening fraction, and cardiac output, without effects on hemodynamics in animal models of myocardial ischemia-induced chronic heart failure. A comparable protective effect to LCZ696 was observed for S086 at an equal molar dose in dog models. In addition, S086 was superior to LCZ696 since it significantly reversed the decrease in left ventricular posterior wall end-systolic thickness.
Conclusion: This animal study suggests that S086 is effective in treating myocardial ischemia-induced chronic heart failure.
Keywords: Angiotensin receptor blocker; Angiotensin receptor-NEP inhibitor; Heart failure; Neprilysin inhibitor.
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.